التفاصيل البيبلوغرافية
| العنوان: |
Extended Use of the Control-IQ Closed-Loop Control System in Children With Type 1 Diabetes. |
| المؤلفون: |
Kanapka, Lauren G., Wadwa, R. Paul, Breton, Marc D., Ruedy, Katrina J., Ekhlaspour, Laya, Forlenza, Gregory P., Cengiz, Eda, Schoelwer, Melissa J., Jost, Emily, Carria, Lori, Emory, Emma, Hsu, Liana J., Weinzimer, Stuart A., DeBoer, Mark D., Buckingham, Bruce A., Oliveri, Mary, Kollman, Craig, Dokken, Betsy B., Cherñavvsky, Daniel, Beck, Roy W. |
| المصدر: |
Diabetes Care; Feb2021, Vol. 44 Issue 2, p473-478, 6p |
| مصطلحات موضوعية: |
TYPE 1 diabetes, CLOSED loop systems, GLYCEMIC control, DIABETIC acidosis, CLINICAL trials, INSULIN therapy, RESEARCH, RESEARCH methodology, HYPOGLYCEMIC agents, BLOOD sugar, MEDICAL cooperation, EVALUATION research, COMPARATIVE studies, RANDOMIZED controlled trials, HYPOGLYCEMIA, INSULIN pumps, RESEARCH funding |
| مستخلص: |
Objective: To further evaluate the safety and efficacy of the Control-IQ closed-loop control (CLC) system in children with type 1 diabetes.Research Design and Methods: After a 16-week randomized clinical trial (RCT) comparing CLC with sensor-augmented pump (SAP) therapy in 101 children 6-13 years old with type 1 diabetes, 22 participants in the SAP group initiated use of the CLC system (referred to as SAP-CLC cohort), and 78 participants in the CLC group continued use of CLC (CLC-CLC cohort) for 12 weeks.Results: In the SAP-CLC cohort, mean percentage of time in range 70-180 mg/dL (TIR) increased from 55 ± 13% using SAP during the RCT to 65 ± 10% using CLC (P < 0.001), with 36% of the cohort achieving TIR >70% plus time <54 mg/dL <1% compared with 14% when using SAP (P = 0.03). Substantial improvement in TIR was seen after the 1st day of CLC. Time <70 mg/dL decreased from 1.80% to 1.34% (P < 0.001). In the CLC-CLC cohort, mean TIR increased from 53 ± 17% prerandomization to 67 ± 10% during the RCT and remained reasonably stable at 66 ± 10% through the 12 weeks post-RCT. No episodes of diabetic ketoacidosis or severe hypoglycemia occurred in either cohort.Conclusions: This further evaluation of the Control-IQ CLC system supports the findings of the preceding RCT that use of a closed-loop system can safely improve glycemic control in children 6-13 years old with type 1 diabetes from the 1st day of use and demonstrates that these improvements can be sustained through 28 weeks of use. [ABSTRACT FROM AUTHOR] |
|
Copyright of Diabetes Care is the property of American Diabetes Association and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder